UK. CBD anti-epilepsy medicine planned by GW Pharmaceuticals
GW Pharmaceuticals may be best known for their Sativex oral spray which gives a 1:1 ratio of THC:CBD. THC and CBD are 2 of the many cannabinoid chemicals found in cannabis. Their new drug is codenamed, interestingly, GWP420 006, and is in phase-1 clinical trials, and has been in development for several years.
GW Pharma claim this is a non-pyschoactive medicine, suggesting a possible THC-free formula (or a very low THC formula). Initial results are encouraging, and GW Pharmaceuticals are highly likely to eventually commercialise this new product once all clinical trials have been completed. Many cannabis users will already be aware of cannabis as an effective medicine for seizures, it will be interesting to see the future peer-reviewed data from the phase-2 and phase-3 trials.
More information can be read on the GW Pharmaceuticals website http://www.gwpharm.com/Phase1Epilepsy.aspx